Cargando…

Editorial: NSAIDs Pharmacogenomics

Detalles Bibliográficos
Autores principales:	Agúndez, José A. G., Formea, Christine, Gaedigk, Andrea, García-Martín, Elena, Gong, Li, Grosser, Tilo, Lee, Craig R., Theken, Katherine N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640121/ https://www.ncbi.nlm.nih.gov/pubmed/34867430 http://dx.doi.org/10.3389/fphar.2021.798447

Ejemplares similares

Editorial: Insights in Pharmacogenetics and Pharmacogenomics: 2021
por: Agúndez, José A. G., et al.
Publicado: (2022)

Editorial: Editor’s feature: negative findings in pharmacogenetics and pharmacogenomics
por: Agúndez, José A. G., et al.
Publicado: (2023)

Editorial: The Potential of Machine Learning in Pharmacogenetics, Pharmacogenomics and Pharmacoepidemiology
por: Garcia-Agundez, Augusto, et al.
Publicado: (2022)

Editorial: The Potential of Machine-learning in Pharmacogenetics, Pharmacogenomics and Pharmacoepidemiology: Volume II
por: Garcia-Agundez, Augusto, et al.
Publicado: (2023)

Pharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity
por: McEvoy, L., et al.
Publicado: (2021)

Clinical practice guidelines for translating pharmacogenomic knowledge to bedside. Focus on anticancer drugs
por: Agúndez, José A. G., et al.
Publicado: (2014)

Pharmacogenomics of Prostaglandin and Leukotriene Receptors
por: Cornejo-García, José A., et al.
Publicado: (2016)

FCERI and Histamine Metabolism Gene Variability in Selective Responders to NSAIDS
por: Amo, Gemma, et al.
Publicado: (2016)

Pharmacogenomics Factors Influencing the Effect of Risperidone on Prolactin Levels in Thai Pediatric Patients With Autism Spectrum Disorder
por: Hongkaew, Yaowaluck, et al.
Publicado: (2021)

Editorial: Pharmacogenomics in neglected populations
por: Botton, Mariana R., et al.
Publicado: (2022)

Editorial: Biomarkers in Drug Hypersensitivity
por: Agúndez, José A. G., et al.
Publicado: (2017)

Lack of Major Involvement of Common CYP2C Gene Polymorphisms in the Risk of Developing Cross-Hypersensitivity to NSAIDs
por: Macías, Yolanda, et al.
Publicado: (2021)

Editorial: Pharmacogenomics and ethnicity: Prevalence and clinical significance of pharmacogenomic biomarkers in indigenous and other populations
por: Patrinos, George P., et al.
Publicado: (2023)

Editorial: The utilization of bench-to-bedside approaches in pharmacogenomics
por: Rytkin, Eric, et al.
Publicado: (2023)

Editorial: Brief research reports in pharmacogenetics and pharmacogenomics: 2022
por: Sessa, Francesco, et al.
Publicado: (2023)

Editorial: Improving cancer chemotherapy through pharmacogenomics: a research topic
por: Quiñones, Luis A., et al.
Publicado: (2015)

Editorial: Big Data, Pharmacogenomics and Real-World Research in Pharmacology
por: Wei, James Cheng-Chung, et al.
Publicado: (2020)

Editorial: Emerging talents in frontiers in pharmacology: pharmacogenetics and pharmacogenomics 2022
por: Klomp, Sylvia D., et al.
Publicado: (2023)

Editorial: From Trial and Error to Individualised Pharmacogenomics-Based Pharmacotherapy in Psychiatry
por: van Westrhenen, R., et al.
Publicado: (2021)

Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain
por: Agúndez, José A. G., et al.
Publicado: (2012)

Editorial: How pharmacogenomics, epigenetics, and data analysis could improve anticancer treatment?
por: Jaafari, Abdeslam, et al.
Publicado: (2022)

Pharmacogenomics in oncology care
por: Filipski, Kelly K., et al.
Publicado: (2014)

NSAID–Gut Microbiota Interactions
por: Maseda, Damian, et al.
Publicado: (2020)

Conference report: inaugural Pharmacogenomics Access & Reimbursement Symposium
por: Rogers, Sara L., et al.
Publicado: (2021)

Ethnic Diversity and Warfarin Pharmacogenomics
por: Asiimwe, Innocent G., et al.
Publicado: (2022)

Pharmacogenomics: What is Next?
por: di Iulio, Julia, et al.
Publicado: (2012)

Pharmacogenomics at the post-pandemic: If not now, then when?
por: Al-Mahayri, Zeina N.
Publicado: (2022)

Editorial: Translation and implementation of pharmacogenomic testing in daily clinical practice: Considering current challenges and future needs
por: Miltyk, Wojciech, et al.
Publicado: (2022)

Whole genome sequencing in pharmacogenomics
por: Katsila, Theodora, et al.
Publicado: (2015)

Pharmacogenomics in clinical trials: an overview
por: Nogueiras-Álvarez, Rita
Publicado: (2023)

Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy
por: Al-Mahayri, Zeina N., et al.
Publicado: (2020)

Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy
por: García-Menaya, Jesús Miguel, et al.
Publicado: (2019)

Impact of domiciliary administration of NSAIDs on COVID-19 hospital outcomes: an unCoVer analysis
por: Salvador, Elena, et al.
Publicado: (2023)

Pharmacogenomics of human P450 oxidoreductase
por: Pandey, Amit V., et al.
Publicado: (2014)

Pharmacogenomics and adverse drug reactions in children
por: Rieder, Michael J., et al.
Publicado: (2014)

Current clinical evidence on pioglitazone pharmacogenomics
por: Kawaguchi-Suzuki, Marina, et al.
Publicado: (2013)

The pharmacogenomic landscape of an Indigenous Australian population
por: Samarasinghe, Sumudu Rangika, et al.
Publicado: (2023)

Editorial: Pharmacogenetics and Pharmacogenomics in Latin America: Ethnic Variability, New Insights in Advances and Perspectives: A RELIVAF-CYTED Initiative
por: Esperón, Patricia, et al.
Publicado: (2022)

Evolution of pharmacogenomic services and implementation of a multi-state pharmacogenomics clinic across a large rural healthcare system
por: Van Heukelom, Joel, et al.
Publicado: (2023)

Use of pharmacogenomics in pediatric renal transplant recipients
por: Medeiros, Mara, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_f89sk4nq85akf6hlh8pvrbjnjs